Cargando…
Prolonged Treatment Response to Pembrolizumab in a Patient with Pretreated Metastatic Colon Cancer and Lynch Syndrome
Pembrolizumab and other immunotherapies now play a prominent role in the treatment of metastatic colon cancer. Clinicians have achieved significant response rates even in heavily pretreated patients, particularly those with mismatched repair deficiencies. The endpoint of pembrolizumab treatment for...
Autores principales: | Keating, Matthew, Giscombe, Lisa, Tannous, Toufic, Hartshorn, Kevan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6745160/ https://www.ncbi.nlm.nih.gov/pubmed/31565451 http://dx.doi.org/10.1155/2019/3847672 |
Ejemplares similares
-
A 64-year-old woman with rapid neurologic decline diagnosed with
Toxoplasma encephalitis after presumed metastatic
cancer
por: Rosso, Claudia, et al.
Publicado: (2021) -
Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer
por: Salman, Pamela, et al.
Publicado: (2018) -
Exceptional Response to Pembrolizumab for Treatment of Metastatic Chemorefractory Endometrial Carcinoma in a Patient with Lynch Syndrome: A Case Report
por: Batman, Samantha, et al.
Publicado: (2023) -
Testicular Germ Cell Tumors: Paraneoplastic Syndromes and the Role of Beta-Human Chorionic Gonadotropin
por: Tannous, Toufic, et al.
Publicado: (2021) -
Primary Refractory Catastrophic Antiphospholipid Syndrome Masquerading as Buerger’s Disease
por: Tannous, Toufic, et al.
Publicado: (2021)